tions had a reduced response of insulin secretion at 30 min and an increase in plasma glucose concentration at 60 min after oral glucose loading as compared with those without mutations. The maximal insulin secretion was delayed in the subjects with mutations (90 min vs 30 min in the subjects without mutations after glucose loading). The significance level of insulin response at 30 min between the two groups was still observed after adjustment for the subject's body mass index (p < 0.05) and steady-state plasma glucose (p < 0.001) levels, but not observed after adjustment for age (p > 0.05). The areas under the curve (AUC) of glucose and insulin responses were no different between the two groups (AUC of glucose: 178.7 ± 33.0 vs 235.9 ± 10.1 mmol/l´min; AUC of insulin: 18353 ± 8051 vs 10643 ± 2479 pmol/l´min). Both basal and stimulated C-peptide levels at 6 min after glucagon injection were not significantly different between the two groups.
To study the effect of the amylin gene mutation on insulin sensitivity, we compared the measured parameters. We found no differences in the body mass index and waist-hip ratio, and the steady-state plasma glucose levels (8.8 ± 1.8 mmol/l vs 10.8 ± 1.6 mmol/l; p > 0.05) between the subjects with and without the amylin gene mutation, indicating the absence of any effect of the mutation on insulin resistance. Previous studies of the patients with amylin gene mutations showed an elevated amylin to insulin molar ratio, indicating a relatively high level of amylin concentration to insulin in these subjects [4] . Chronic elevation of the amylin concentration in transgenic animals, however, suggests amylin has no effect on insulin actions [5] . Our studies in humans might agree with these data as we could not show any effect of the amylin gene mutation on insulin sensitivity.
In conclusion, our data indicate the S20G mutation of the amylin gene does not play a role in the pathogenesis of diabetes mellitus. Amylin has been shown to downregulate glucose-induced insulin biosynthesis and secretion by affecting the insulin mRNA and insulin content [6, 7] . We also found a small reduction in early insulin secretion in the non-diabetic subjects carrying amylin gene mutations although this effect was very mild and was not observed after adjustment for age. Whether this effect on beta cells is caused by high levels of S20G-amylin or direct beta-cell toxicity due to increased amyloid fibril formation by S20G-amylin deserves further studies. Our data are not in agreement with the study by Sakagashira et al. [4] . Whether this is due to ethnic differences or genetic heterogeneity is not clear. Both studies, however, conclude that the amylin gene mutation does not seem to play a major role in the pathogenesis of Type II diabetes. Insulin sensitivity is inversely correlated with plasma cholesteryl ester transfer protein (CETP)
Dear Sir, Late-onset (N 30 yr) Type I (insulin-dependent) diabetes mellitus is rare in Japanese and characterized by relatively high plasma HDL-cholesterol (C) concentrations. We studied 17 (12 women) Type I diabetic patients aged 50.9 ± 11.8 years (mean ± SD) with the following clinical features: age at onset 41.9 ± 9.8 years, episode of keto-acidosis 47.1 %, ketosis proneness 94.1 %, positive anti-GAD antibody 41.2 %, BMI 21.9 ± 2.3, HbA 1c 8.7 ± 1.6 %, insulin dose 34.8 ± 14.1 U/day, total C 5.5 ± 0.9 mmol/L, HDL-C 2.4 ± 0.6 mmol/L (2 men > 2.1 mmol/L, 8 women > 2.6 mmol/L), and triglyceride 0.87 ± 0.45 mmol/L. When compared with counterparts comprising 29 patients (24 women) who were recruited randomly and had early-onset (< 20 year) Type I diabetes and similar insulin dosage (43.4 ± 13.5 U/day) and glycaemic control (HbA 1c 8.6 ± 1.3 %), the mean plasma HDL-C concentration was higher in the late-onset group (p < 0.001 from 1.6 ± 0.3 mmol/L). To examine the difference in plasma HDL-C concentrations between the two groups, we measured the degree of insulin sensitivity (GIR) using the euglycaemic hyperinsulinaemic clamp method described previously [1] . The mean GIR value was higher in the late-onset Type I diabetes group (5.47 ± 1.49 vs 4.51 ± 1.47 mg × kg 1 × min 1 , p < 0.05). These results were to be expected because plasma HDL-C concentration and insulin resistance are well known to relate inversely both in non-diabetic subjects and those with Type II (non-insulin-dependent) diabetes mellitus. Further to explore a link between insulin sensitivity and plasma HDL-C, plasma concentrations of cholesteryl ester transfer protein (CETP) and HDL subclasses were determined by the enzyme immunoassay and by the ultra-centrifugation method, respectively.
The importance of CETP in HDL-C metabolism has been established since the discovery of CETP deficiency caused by mutation in the CETP gene, which was associated with extremely high plasma HDL-C concentrations [2] . There were inverse correlations between GIR value and CETP (r = ± 0.585, p < 0.05, Fig. 1) , and between CETP and HDL2 (r = 0.622, p < 0.01). On the contrary, plasma CETP showed no correlation with any variables of HbA 1c , insulin dose, BMI, and HDL3. These results indicate that higher plasma HDL-C concentrations found in our late-onset Type I diabetic patients could be explained by the insulin sensitivity-associated modulation of CETP mass. It has been shown that long-term exercise training decreases plasma CETP and increases HDL-C in healthy subjects, and this occurs independently of weight change [3] . Our findings show the close relation between insulin sensitivity and plasma CETP in these Type I diabetic patients. Furthermore, this agrees in part with the evidence that the higher the plasma insulin concentration (more insulin resistant), the greater the fractional catabolic rate of HDL and the lower the plasma HDL-C concentration in Type II diabetic patients [4] . Also our observations are not inconsistent with results that cholesteryl ester transfer (CET) is accelerated in Type I diabetic patients with normolipidaemia [5] . Because CET activity was shown to correlate with plasma concentration of CETP measured by RIA [6] , we suppose that the rate of CET is reduced in this insulin-sensitive group of Type I diabetic patients. In fact, plasma HDL2 subclass, a preferred donor for CETP, increased in parallel with HDL-C concentrations.
We conclude that insulin sensitivity is one of the factors responsible for physiological variation of plasma CETP concentrations.
Yours sincerely, T. Wasada, K. Katsumori, C. Watanabe, R. Kawahara, Y. Iwamoto Fig. 1 . Correlation between glucose infusion rate (GIR), an index of whole-body insulin sensitivity and plasma concentration of CETP in 17 late-onset Type I diabetic patients
